SG11201906987RA - Combination of a ppar agonist with a fxr agonist - Google Patents

Combination of a ppar agonist with a fxr agonist

Info

Publication number
SG11201906987RA
SG11201906987RA SG11201906987RA SG11201906987RA SG11201906987RA SG 11201906987R A SG11201906987R A SG 11201906987RA SG 11201906987R A SG11201906987R A SG 11201906987RA SG 11201906987R A SG11201906987R A SG 11201906987RA SG 11201906987R A SG11201906987R A SG 11201906987RA
Authority
SG
Singapore
Prior art keywords
international
pct
agonist
combination
loos
Prior art date
Application number
SG11201906987RA
Inventor
Benoît Noel
Robert Walczak
Carole Belanger
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201906987RA publication Critical patent/SG11201906987RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ill Hu omits I iolo Ell 1011 00 1110 011 (10) International Publication Number WO 2018/153933 Al 30 August 2018 (30.08.2018) WIP0 I PCT (51) International Patent Classification: A61K 31/192 (2006.01) A61K 9/14 (2006.01) A61K 31/575 (2006.01) A61P 29/00 (2006.01) A61P 1/16 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/EP2018/054305 (22) International Filing Date: 21 February 2018 (21.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17157279.5 21 February 2017 (21.02.2017) EP 17162161.8 21 March 2017 (21.03.2017) EP 17165131.8 05 April 2017 (05.04.2017) EP (71) Applicant: GENFIT [FR/FR]; 885, avenue Eugene Avinee, 59120 Loos (FR). (72) Inventors: NOEL, Benoit; 9 me Leonard Danel, 59120 Loos (FR). WALCZAK, Robert; Residence Parc d'Isly, 13B me Delezenne, 59000 Lille (FR). BELANGER, Car- ole; 3 allee du Verger, 59910 Bondues (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 Paris (FR). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 01 with sequence listing part of description (Rule 5.2(a)) 1-1 1-1 (54) Title: COMBINATION OF A PPAR AGONIST WITH A FXR AGONIST C (57) : The present invention relates to a combination of active ingredients for use in the treatment of diseases.
SG11201906987RA 2017-02-21 2018-02-21 Combination of a ppar agonist with a fxr agonist SG11201906987RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17157279 2017-02-21
EP17162161 2017-03-21
EP17165131 2017-04-05
PCT/EP2018/054305 WO2018153933A1 (en) 2017-02-21 2018-02-21 Combination of a ppar agonist with a fxr agonist

Publications (1)

Publication Number Publication Date
SG11201906987RA true SG11201906987RA (en) 2019-09-27

Family

ID=61223919

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906987RA SG11201906987RA (en) 2017-02-21 2018-02-21 Combination of a ppar agonist with a fxr agonist

Country Status (15)

Country Link
US (1) US20200054589A1 (en)
EP (1) EP3585374B1 (en)
JP (1) JP2020508316A (en)
KR (1) KR20190117632A (en)
CN (1) CN110300580A (en)
AU (1) AU2018223146B2 (en)
BR (1) BR112019017312A2 (en)
CA (1) CA3051776A1 (en)
ES (1) ES2959842T3 (en)
IL (1) IL268426A (en)
MX (1) MX2019009908A (en)
PH (1) PH12019501905A1 (en)
SG (1) SG11201906987RA (en)
WO (1) WO2018153933A1 (en)
ZA (1) ZA201906100B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
IL298144A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combination treatment of liver disorders
JP2023525570A (en) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド Concomitant treatment of liver damage
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor
WO2022051321A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
CN116761800A (en) * 2020-09-11 2023-09-15 拓臻制药公司 Solid dispersion formulations of FXR agonists
TW202317110A (en) * 2021-07-06 2023-05-01 中國大陸商甘萊製藥有限公司 Combination therapy for treatment of liver diseases

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT364688B (en) 1979-07-19 1981-11-10 Gergely Gerhard METHOD FOR PRODUCING A FLAVOR PRODUCT
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
FR2841900B1 (en) 2002-07-08 2007-03-02 Genfit S A NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES
ITMI20021532A1 (en) 2002-07-12 2004-01-12 Roberto Pellicciari CHEMICAL COMPOUNDS
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
FR2857361B1 (en) 2003-07-08 2005-09-09 Genfit S A PREPARATION OF 1,3-DIPHENYPROP-2-¼n-1-one DERIVATIVES
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
CA2651378C (en) 2006-05-24 2012-08-28 Eli Lilly And Company Fxr agonists
PE20080259A1 (en) 2006-05-24 2008-04-10 Lilly Co Eli COMPOUNDS AND METHODS TO MODULATE FXR
CA2655395C (en) 2006-06-29 2011-10-11 F.Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
MX2009013624A (en) 2007-06-13 2010-04-27 Glaxosmithkline Llc Farnesoid x receptor agonists.
AU2008270784A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
WO2009027264A1 (en) 2007-08-27 2009-03-05 F. Hoffmann-La Roche Ag Benzimidazole derivatives used as fxr agonists
JP5222953B2 (en) 2007-11-15 2013-06-26 エフ．ホフマン−ラ ロシュ アーゲー Benzimidazole derivatives and their use as FXR agonists
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
MX2011002794A (en) 2008-09-25 2011-04-05 Hoffmann La Roche 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases.
AU2009295967A1 (en) 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8309581B2 (en) 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
SG185397A1 (en) 2010-05-17 2012-12-28 Genfit Improved preparation of chalcone derivatives
CU24152B1 (en) 2010-12-20 2016-02-29 Irm Llc 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ME03082B (en) 2013-05-14 2019-01-20 Intercept Pharmaceuticals Inc 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2015138986A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
US10266560B2 (en) 2014-11-06 2019-04-23 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (en) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3253382B1 (en) * 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
KR20170131644A (en) * 2015-03-26 2017-11-29 티3디 테라퓨틱스, 인크. Treatment of Liver Disease with Indan-acetic Acid Derivatives

Also Published As

Publication number Publication date
MX2019009908A (en) 2019-10-14
AU2018223146A1 (en) 2019-09-05
EP3585374B1 (en) 2023-07-19
PH12019501905A1 (en) 2020-06-08
BR112019017312A2 (en) 2020-04-14
US20200054589A1 (en) 2020-02-20
CA3051776A1 (en) 2018-08-30
IL268426A (en) 2019-09-26
JP2020508316A (en) 2020-03-19
KR20190117632A (en) 2019-10-16
AU2018223146B2 (en) 2023-12-21
CN110300580A (en) 2019-10-01
WO2018153933A1 (en) 2018-08-30
ZA201906100B (en) 2023-08-30
ES2959842T3 (en) 2024-02-28
EP3585374A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201907034PA (en) Methods of treating influenza
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201909949XA (en) Targeted immunotolerance
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201809702SA (en) Benzenesulfonamide compounds and their use as therapeutic agents
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof